Found: 24
Select item for more details and to access through your institution.
The need for a strategic therapeutic approach: multiple sclerosis in check.
- Published in:
- Therapeutic Advances in Chronic Disease, 2022, p. 1, doi. 10.1177/20406223211063032
- By:
- Publication type:
- Article
The need for a strategic therapeutic approach: multiple sclerosis in check.
- Published in:
- Therapeutic Advances in Chronic Disease, 2022, p. 1, doi. 10.1177/20406223211063032
- By:
- Publication type:
- Article
Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.02669
- By:
- Publication type:
- Article
Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis.
- Published in:
- Frontiers in Neurology, 2021, v. 11, p. N.PAG, doi. 10.3389/fneur.2021.650530
- By:
- Publication type:
- Article
Should We Use Clinical Tools to Identify Disease Progression?
- Published in:
- Frontiers in Neurology, 2021, v. 11, p. N.PAG, doi. 10.3389/fneur.2020.628542
- By:
- Publication type:
- Article
Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 11, p. 3177, doi. 10.3390/cells10113177
- By:
- Publication type:
- Article
Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 14, p. 1849, doi. 10.1177/13524585231200719
- By:
- Publication type:
- Article
Letter to the editor regarding "Therapeutic drug monitoring of natalizumab".
- Published in:
- 2020
- By:
- Publication type:
- Letter
Natalizumab during pregnancy and lactation.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 12, p. 1627, doi. 10.1177/1352458517728813
- By:
- Publication type:
- Article
Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 10, p. 1337, doi. 10.1177/1352458517720043
- By:
- Publication type:
- Article
Letter to the editor on the paper: “The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Early central vs. peripheral immunological and neurobiological effects of fingolimod—a longitudinal study.
- Published in:
- Journal of Molecular Medicine, 2019, v. 97, n. 9, p. 1263, doi. 10.1007/s00109-019-01812-x
- By:
- Publication type:
- Article
SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma.
- Published in:
- Vaccines, 2024, v. 12, n. 6, p. 684, doi. 10.3390/vaccines12060684
- By:
- Publication type:
- Article
Insights from Real-World Practice: The Dynamics of SARS-CoV-2 Infections and Vaccinations in a Large German Multiple Sclerosis Cohort.
- Published in:
- Vaccines, 2024, v. 12, n. 3, p. 265, doi. 10.3390/vaccines12030265
- By:
- Publication type:
- Article
Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.715195
- By:
- Publication type:
- Article
Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1404316
- By:
- Publication type:
- Article
A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.
- Published in:
- Journal of Neurology, 2021, v. 268, n. 4, p. 1210, doi. 10.1007/s00415-019-09489-5
- By:
- Publication type:
- Article
Can ChatGPT explain it? Use of artificial intelligence in multiple sclerosis communication.
- Published in:
- Neurological Research & Practice, 2023, v. 5, n. 1, p. 1, doi. 10.1186/s42466-023-00270-8
- By:
- Publication type:
- Article
Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting.
- Published in:
- Therapeutic Advances in Chronic Disease, 2019, v. 10, p. 1, doi. 10.1177/2040622319835136
- By:
- Publication type:
- Article
Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting.
- Published in:
- Therapeutic Advances in Chronic Disease, 2019, v. 10, p. 1, doi. 10.1177/2040622319835136
- By:
- Publication type:
- Article
Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2023, p. 1, doi. 10.1177/17562864221150040
- By:
- Publication type:
- Article
Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2023, v. 16, p. 1, doi. 10.1177/17562864221150040
- By:
- Publication type:
- Article
Influence of Pre-Analytic Conditions on Quantity of Lymphocytes.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 17, p. 13479, doi. 10.3390/ijms241713479
- By:
- Publication type:
- Article